EGFR tyrosine kinase inhibitor (EGFR TKI, such as gefitinib and erlotinib) and EML4/ALK inhibitor (Crizotinib) have achieved better results in the clinical therapy of advanced NSCLC [2,3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.